# US 2024/0003879 A1 · Methods for diagnosis and monitoring of toxic epidermal necrolysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003879 A1
- Document ID: US20240003879A1
- Status: Published application
- Kind: A1
- Application number: 18/038,970
- Filed: 2021-11-26
- Published: 2024-01-04
- Earliest claimed: 2020-11-27
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure De Lyon; Hospices Civils De Lyon; Universite Claude Bernard Lyon 1
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Centre National De La Recherche Scientifique (Cnrs); Ecole Normale SupéRieure De Lyon; Hospices Civils De Lyon; Université Claude Bernard - Lyon 1
- Inventors: Marc VOCANSON; Axel VILLANI; Audrey NOSBAUM; Aurore ROZIERES
- Web page: https://patentgrep.com/patent/US20240003879A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/56972: {White blood cells}
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/70517: {CD8}
- C07K 14/7158: {for chemokines}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/2497: {hydrolysing N- glycosyl compounds (3.2.2)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12Y 302/02006: NAD(P)+ nucleosidase (3.2.2.6)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- G01N 2333/70517: CD8
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

In the present invention, inventors investigate the representation of T cell subsets in Toxic epidermal necrolysis (TEN) a life-threatening cutaneous adverse drug reaction (cADR), characterized by massive epidermal necrosis. To better understand why skin symptoms are so severe in TEN disease, inventors conducted a prospective immunophenotyping study on skin samples and blood from 18 TEN patients, using mass cytometry and next generation TCR sequencing. Deep sequencing of the T cell receptor CDR3 repertoire revealed massive expansion of unique CDR3 clonotypes in blister cells. Over-represented clonotypes were mainly effector memory CD8+CD45RA−CCR7− T cells, and expressed high levels of cytotoxic (Granulysin and Granzymes A & B) and activation (CD38) markers. Thus present invention relates to non-invasive, specific and rapid methods for diagnostic and monitoring Toxic Epidermal Necrolysis. More specifically present invention relates to methods for diagnosis and/or monitoring of Toxic Epidermal Necrolysis through detection of a specific population of T lymphocytes in a subject. The present invention also relates to a method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof.

## Claims

### Claim 1

A method for assessing a subject's risk of having or developing Toxic Epidermal Necrolysis and treating the subject, comprising i) determining in a sample obtained from the subject the level of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ markers, and ii) administering a CD38 inhibitor to a subject identified as having a level of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ markers that is higher than a corresponding reference value.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the sample is a blood sample or immune primary cells or a blister sample or a skin sample.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the immune primary cells are selected from the group consisting of PBMC, WBC and T lymphocytes.

### Claim 4

A method for monitoring and treating a Toxic Epidermal Necrolysis comprising i) determining the level of a population of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ markers in a sample obtained from the subject at a first specific time of the disease, ii) determining the level of a population of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ markers in a sample obtained from the subject at a second specific time of the disease, and iii) administering a CD38 inhibitor to a subject identified as having a level determined at step ii) that is higher than the level determined at step i).

### Claim 5

An in vitro method for monitoring the treatment of Toxic Epidermal Necrolysis comprising the steps of i) determining the level of a population of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ in a sample obtained from the subject before the treatment, ii) determining the level of a population of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ markers in a sample obtained from the subject after the treatment”, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the treatment is efficient when the level determined at step ii) is lower than the level determined at step i).

### Claim 6 (depends on 4)

The in vitro method for monitoring according to claim 4, wherein the sample is a blood sample or immune primary cells or blister sample or skin sample.

### Claim 7 (depends on 4)

The in vitro method for monitoring according to claim 4, wherein the immune primary cells selected from the group consisting of PBMC, WBC and T lymphocytes.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the level of the population of T lymphocytes having cell surface expression of CD8+CD45RA−CCR7−CD38+ is determined by clonal expansion of said population.

### Claim 9

A method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof, comprising,
administering to the subject a therapeutically effective amount of a CD38 inhibitor.

### Claim 10 (depends on 8)

The method according to claim 8 wherein the CD38 inhibitors is selected from:
a) an inhibitor of CD38 activity
and/or
b) an inhibitor of CD38 gene expression.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said inhibitor of CD38 activity is a small organic molecule, an antibody, a CAR T cell or an aptamer.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the antibody is selected from the group consisting Daratumumab, Isatuximab, MOR202, TAK-079, TAK-169, AMG424 or GBR 1342.

### Claim 13 (depends on 10)

The method according to claim 10 wherein the inhibitor of CD38 gene expression is an antisense oligonucleotide, a nuclease, siRNA, shRNA, or ribozyme nucleic acid sequence.

### Claim 14 (depends on 1, 9)

The method according to claim 9, wherein the subject is identified having a high level of T lymphocytes CD8+CD45RA−CCR7−CD38+ in a biological sample, wherein the level by the methods of claim 1.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the biological sample is a blood sample or immune primary cells or a skin sample.

### Claim 16

(canceled)
